Evidence map›Paper›PMID 34426808›Full record

ArticleResearch square2021

Impact of COVID-19 on routine malaria indicators in Uganda: An interrupted time series analysis.

Jane Frances Namuganga, Jessica Briggs, Michelle E Roh, Jaffer Okiring, Yasin Kisambira, Asadu Sserwanga, James Apollo Kapisi, Emmanuel Arinaitwe, Chris Ebong, Isaac Ssewanyana and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Jane Frances NamugangaInfectious Diseases Research Collaboration.ORCID 0000-0001-8452-4247
Jessica BriggsUniversity of California San Francisco.
Michelle E RohUniversity of California San Francisco.
Jaffer OkiringIDRC: Infectious Diseases Research Collaboration.
Yasin KisambiraIDRC: Infectious Diseases Research Collaboration.
Asadu SserwangaInfectious Diseases Research Collaboration.
James Apollo KapisiInfectious Diseases Research Collaboration.
Emmanuel ArinaitweInfectious Diseases Research Collaboration.
Chris EbongInfectious Diseases Research Collaboration.
Isaac SsewanyanaIDRC: Infectious Diseases Research Collaboration.
Bryan GreenhouseUniversity of California San Francisco.
Catherine Maiteki-SsebuguziMOH: Republic of Uganda Ministry of Health.
Moses R KamyaIDRC: Infectious Diseases Research Collaboration.
Sarah G StaedkeLondon School of Hygiene & Tropical Medicine.
Grant DorseyUniversity of California San Francisco.
Joaniter I NankabirwaInfectious Diseases Research Collaboration.
Infectious Diseases Research Collaboration · UGUniversity of California, San Francisco · USLondon School of Hygiene & Tropical Medicine · GBMinistry of Health · UG

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in UgandaK43TW010365 · FIC · INFECTIOUS DISEASES RES COLLABORATION · PI NANKABIRWA, JOANITER IMMACULATE · 2017 to 2021
$514k
FIC NIH HHS D43 TW010526FIC NIH HHS K43 TW010365Gates Foundation INV-017894NIAID NIH HHS K24 AI144048NIAID NIH HHS U19 AI089674
6 · The paper itself

Abstract

Background In March 2020, the government of Uganda implemented a strict lockdown policy in response to the COVID-19 pandemic. We performed an interrupted time series analysis (ITSA) to assess whether major changes in healthcare seeking behavior, malaria burden, and case management occurred after the onset of the COVID-19 epidemic. Methods Individual level data from all outpatient visits occurring from April 2017 through March 2021 at 17 facilities were analyzed. Outcomes included total outpatient visits, malaria cases, non-malarial visits, proportion of visits with suspected malaria, proportion of patients tested using rapid diagnostic tests (RDTs), and proportion of malaria cases prescribed artemether-lumefantrine (AL). Pre-COVID trends measured over a three-year period were extrapolated into the post-COVID period (April 2020- March 2021) using Poisson regression with generalized estimating equations or fractional regression. Effects of COVID-19 were estimated over the 12-month post-COVID period by dividing observed values by the predicted values and expressed as ratios. Results A total of 1,442,737 outpatient visits were recorded. Malaria was suspected in 55.3% of visits and 98.8% of these had a malaria diagnostic test performed. ITSA showed no differences in the observed versus predicted total outpatient visits, malaria cases, non-malarial visits, or proportion of visits with suspected malaria. However, in the second six months of the post-COVID period, there was a smaller mean proportion of patients tested with RDTs compared to predicted (Relative Prevalence Ratio (RPR) = 0.87, CI [0.78, 0.97]) and a smaller mean proportion of malaria cases prescribed AL (RPR = 0.94, CI [0.90, 0.99]. Conclusions There was evidence for a modest decrease in the proportion of RDTs used for malaria diagnosis and the proportion of patients prescribed AL in the second half of the post-COVID year, while other malaria indicators remained stable. Continued surveillance will be essential to monitor for changes in trends in malaria indicators so that Uganda can quickly and flexibly respond to challenges imposed by COVID-19.

Identifiers

PMID34426808
PMCPMC8382131
OpenAlexW3193340519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.